BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22669291)

  • 1. UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study.
    Wang YH; Trucksis M; McElwee JJ; Wong PH; Maciolek C; Thompson CD; Prueksaritanont T; Garrett GC; Declercq R; Vets E; Willson KJ; Smith RC; Klappenbach JA; Opiteck GJ; Tsou JA; Gibson C; Laethem T; Panorchan P; Iwamoto M; Shaw PM; Wagner JA; Harrelson JC
    Clin Pharmacol Ther; 2012 Jul; 92(1):96-102. PubMed ID: 22669291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions
    Kahma H; Filppula AM; Neuvonen M; Tarkiainen EK; Tornio A; Holmberg MT; Itkonen MK; Finel M; Neuvonen PJ; Niemi M; Backman JT
    Drug Metab Dispos; 2018 Feb; 46(2):141-150. PubMed ID: 29138287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes.
    Lazarus P; Zheng Y; Runkle EA; Muscat JE; Wiener D
    Pharmacogenet Genomics; 2005 Nov; 15(11):769-78. PubMed ID: 16220109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers.
    Chen SM; Atchley DH; Murphy MA; Gurley BJ; Kamdem LK
    J Clin Pharmacol; 2016 Jul; 56(7):875-84. PubMed ID: 26608382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms.
    Chen G; Giambrone NE; Dluzen DF; Muscat JE; Berg A; Gallagher CJ; Lazarus P
    Cancer Res; 2010 Oct; 70(19):7543-52. PubMed ID: 20876810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the UGT2B17 deletion in exemestane pharmacogenetics.
    Luo S; Chen G; Truica C; Baird CC; Leitzel K; Lazarus P
    Pharmacogenomics J; 2018 Apr; 18(2):295-300. PubMed ID: 28534527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative characterization of UDP-glucuronosyltransferase 2B17 in human liver and intestine and its role in testosterone first-pass metabolism.
    Zhang H; Basit A; Busch D; Yabut K; Bhatt DK; Drozdzik M; Ostrowski M; Li A; Collins C; Oswald S; Prasad B
    Biochem Pharmacol; 2018 Oct; 156():32-42. PubMed ID: 30086285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men.
    Swanson C; Mellström D; Lorentzon M; Vandenput L; Jakobsson J; Rane A; Karlsson M; Ljunggren O; Smith U; Eriksson AL; Bélanger A; Labrie F; Ohlsson C
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4878-82. PubMed ID: 17698910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucuronidation of trans-3'-hydroxycotinine by UGT2B17 and UGT2B10.
    Chen G; Giambrone NE; Lazarus P
    Pharmacogenet Genomics; 2012 Mar; 22(3):183-90. PubMed ID: 22228205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between Glucuronidation Genotypes and Urinary NNAL Metabolic Phenotypes in Smokers.
    Chen G; Luo S; Kozlovich S; Lazarus P
    Cancer Epidemiol Biomarkers Prev; 2016 Jul; 25(7):1175-1184. PubMed ID: 27197298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent.
    Stringer F; Scott G; Valbuena M; Kinley J; Nishihara M; Urquhart R
    Eur J Clin Pharmacol; 2013 Mar; 69(3):423-30. PubMed ID: 22960998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normalized Testosterone Glucuronide as a Potential Urinary Biomarker for Highly Variable UGT2B17 in Children 7-18 Years.
    Zhang H; Basit A; Wolford C; Chen KF; Gaedigk A; Lin YS; Leeder JS; Prasad B
    Clin Pharmacol Ther; 2020 May; 107(5):1149-1158. PubMed ID: 31900930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiological investigation of the UGT2B17 polymorphism in doping control urine samples and its correlation to T/E ratios.
    Anielski P; Simmchen J; Wassill L; Ganghofner D; Thieme D
    Drug Test Anal; 2011 Oct; 3(10):645-51. PubMed ID: 21928278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer.
    Wong NS; Seah EZh; Wang LZ; Yeo WL; Yap HL; Chuah B; Lim YW; Ang PC; Tai BC; Lim R; Goh BC; Lee SC
    Pharmacogenet Genomics; 2011 Nov; 21(11):760-8. PubMed ID: 21849928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of testosterone enanthate dependent on genetic variation in the phosphodiesterase 7B but not on the uridine 5'-diphospho-glucuronosyltransferase (UGT2B17) gene.
    Ekström L; Schulze JJ; Guillemette C; Belanger A; Rane A
    Pharmacogenet Genomics; 2011 Jun; 21(6):325-32. PubMed ID: 21383644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer with variants in CYP17 and UGT2B17 genes: a meta-analysis.
    Cai L; Huang W; Chou KC
    Protein Pept Lett; 2012 Jan; 19(1):62-9. PubMed ID: 21919858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
    Kamdem LK; Xi J; Clark BL; Gregory BJ; Kidwell KM; Storniolo AM; Stearns V; Hayes DF; Gersch CL; Rae JM; Henry NL; Hertz DL
    Breast Cancer Res Treat; 2019 Jun; 175(2):297-303. PubMed ID: 30747308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intestinal Metabolism of Diclofenac by Polymorphic UGT2B17 Correlates with its Highly Variable Pharmacokinetics and Safety across Populations.
    Ahire D; Heyward S; Prasad B
    Clin Pharmacol Ther; 2023 Jul; 114(1):161-172. PubMed ID: 37042794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk.
    Park JY; Tanner JP; Sellers TA; Huang Y; Stevens CK; Dossett N; Shankar RA; Zachariah B; Heysek R; Pow-Sang J
    Urology; 2007 Aug; 70(2):374-9. PubMed ID: 17826523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex differences in UDP-glucuronosyltransferase 2B17 expression and activity.
    Gallagher CJ; Balliet RM; Sun D; Chen G; Lazarus P
    Drug Metab Dispos; 2010 Dec; 38(12):2204-9. PubMed ID: 20810538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.